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Abstract: In the search for the ideal model of tumours, the use of three-dimensional in vitro models
is advancing rapidly. These are intended to mimic the in vivo properties of the tumours which affect
cancer development, progression and drug sensitivity, and take into account cell–cell interactions,
adhesion and invasiveness. Importantly, it is hoped that successful recapitulation of the structure
and function of the tissue will predict patient response, permitting the development of personalized
therapy in a timely manner applicable to the clinic. Furthermore, the use of co-culture systems will
allow the role of the tumour microenvironment and tissue–tissue interactions to be taken into account
and should lead to more accurate predictions of tumour development and responses to drugs. In this
review, the relative merits and limitations of patient-derived organoids will be discussed compared
to other in vitro and ex vivo cancer models. We will focus on their use as models for drug testing
and personalized therapy and how these may be improved. Developments in technology will also
be considered, including the use of microfluidics, 3D bioprinting, cryopreservation and circulating
tumour cell-derived organoids. These have the potential to enhance the consistency, accessibility and
availability of these models.
Keywords: organoids; patient; tumour; drug screening
1. Introduction
Organoids are three-dimensional cultures derived from primary cells which have
similar architectures and functions to in vivo organs and may bridge the gap between 2D
cultures and in vivo animal models [1]. Organoids retain the histological architectures,
genomic landscapes and gene expression profiles of their parental tumours, even after
long-term culture, and are amenable for biomarker identification and high-throughput
drug screening in vitro [2–4]. Tumours are characterized by their heterogeneity and high
frequency of genetic and molecular aberrations. Therefore, effective organoid cultures
must conserve the characteristics of the original tumour as well as those differing from non-
tumour tissue. Importantly, the characteristics of the tumours should also be maintained in
the organoids at different passages, and this has been demonstrated in organoids derived
from colorectal and gastric cancer [3,5,6].
The relative merits and drawbacks of 2D and 3D cultures have been previously dis-
cussed in depth elsewhere [1,7–10]. While two-dimensional cell line cultures are convenient
and easy to use, they are often unrepresentative of primary tumours and do not predict
their responses to therapy [11], thus contributing to the low success rate of clinical trials [12].
The use of a relatively small bank of cell lines also does not represent the heterogeneity of
tumours, whereas the intratumour and intrapatient molecular heterogeneity of the parental
tissue is retained in three-dimensional organoids derived from patient tissue [3,13,14],
providing a more valid model and potentially aiding personalized therapy. It is anticipated
that these organoids (patient-derived organoids, PDO) will contribute to the approaches
of short-term culture and xenotransplantation [7]. Furthermore, organoids derived from
Int. J. Mol. Sci. 2021, 22, 3483. https://doi.org/10.3390/ijms22073483 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 3483 2 of 15
patient tissue can be xenografted into immune-deficient mice, and these patient-derived
tumour xenografts (PDXs) provide improvements over standard cell-line xenograft models.
Although these PDXs are a useful model of metastatic potential, drug responsiveness
and tumour architecture [15], their main limitations remain as the cost involved; the time
required for tumour growth, which will usually be several months; and they may become
clonally distinct from the originating PDOs [11,16]. The growth of tumours in mice is
also affected by mouse-specific evolution [17], which influences their therapeutic response,
and the limited appropriateness of immunocompromised mice, especially for assessing
potential immunotherapies. Although organoids are more costly and require more time
to become established when compared to 2D cell cultures or even 3D spheroids, they
more closely resemble the primary tumour regarding their morphological, genetic and
histological characteristics. One major advantage of using organoids is the potential to
obtain tumour and non-tumour tissue from the same patient. Some of the pros and cons
associated with the current methods for establishing PDO cultures are summarized in
Table 1.
Table 1. Advantages and disadvantages of the more common methods of establishing patient-derived
organoids.
Advantage Disadvantage
Cheaper and more rapid than xenografts More expensive than 2D culture
Retain key features of tumours Time-consuming
Allows repeated sampling from patients High-throughput screening not fullydeveloped
Can predict response to therapy Limited availability of expertise
2. Establishment of Organoids
Human tumour organoids can be generated either directly from tumour tissues or by
the genetic modification of organoids developed from normal tissues, such as using CRISPR
gene editing. Organoids from tumour tissues are established by culturing cells, which
have been dissociated from the tissue, in 3D semisolid extracellular matrix scaffolds in a
defined medium containing appropriate growth factors [18,19]. The presence of a synthetic
basement membrane reproduces the in vivo extracellular matrix (ECM) [20]. Growth factor
cocktails vary according to the source tumour, but often contain combinations of Wnt,
R-Spondin-1 (a Wnt amplifier), epidermal growth factor (EGF), prostaglandin E2, fibroblast
growth factor 10 (FGF10), noggin (inhibitor of bone morphogenetic protein signalling),
A83-01 (inhibitor of TGF-signalling), SB202190 (p38 inhibitor) and Y-27632 (Rho/ROCK
kinase inhibitor) [21]. However, it may be useful in the future to develop media containing
the relevant supplements and growth factors, as this has previously been demonstrated to
improve the metabolic fidelity and biological relevance for in vitro models [22]. Organoids
which maintain the morphological and histological features of the original tumour have
been developed to establish and culture PDOs from many common tumour types, including
glioblastoma [23], breast [24], pancreas [25], prostate [26,27], liver [28], lung [4,29] and
colon [30], with varying degrees of success and reproducibility.
Limitations of organoid cultures include the tissue-specific nature of organoid es-
tablishment, with not all tumour tissues being suitable for organoid establishment. The
availability of fresh tumour tissue and the expertise associated with their establishment and
growth may also preclude some laboratories from utilising these models. The generation
of biobanks of organoids may assist these laboratories, but this is often hampered by the
lack of standardized protocols for tissue handling, processing and cryopreservation, which
may account for the relatively low success rate of the re-establishment of organoids after
cryopreservation [31]. However, methods are being developed to overcome this, with the
potential of maintaining cancer-stem-cell features that may facilitate organoid development.
Refined cryopreservation solutions have also led to improvements in the recovery rates of
organoids derived from several tumour types, including pancreatic and breast tumours,
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retaining their morphological and histological features [24,32]. Some of the limitations of
using organoids, which can deter researchers from using these models, or hinder their
more widespread use, are summarized in Table 2, along with some potential solutions.
Table 2. Limitations of organoid establishment and potential solutions. The widespread use of
organoids may be hindered in some laboratories by lack of expertise, protocols and availability of
suitable tissue, and some simple solutions may be possible to overcome these.
Limitations Potential Solutions
Labour intensive Development of high-throughput systems
Non-standardized methods Adaption of standard protocols
Different culture medium between labs Formulation of commercialmedia/supplements
Collaboration between distant labs Improved freezing protocols
Absence of tumour microenvironment Evolution of co-culture models
Availability of tissue Increased access to biobanksUse of circulating tumour cells
3. Drug Screening Using Organoids
Patient-derived organoids can be used to study drug resistance, metabolism, differen-
tiation and cancer gene function, and as will be discussed here, they have been extensively
utilized for the screening of potential anti-cancer agents. Drug screening, however, is not
limited to cancer therapies, and organoids have also been used successfully to screen drugs
for a variety of other diseases, including cystic fibrosis [33] and Zika virus infection [34],
further indicating the usefulness of these models. It is anticipated that drug screening
using organoids will predict the response in patients, and the value of PDOs in predicting
response to chemotherapy, targeted therapy and radiotherapy is being explored. The data
obtained in vitro would then be able to predict patient outcomes in the clinic, in contrast to
cell lines, which often fail to recapitulate the situation observed in patients. Importantly, it
has already been demonstrated that this is often the case, with the response to therapy in
patients paralleling the chemosensitivity observed in corresponding PDOs derived from
a wide range of cancer types, such as pancreatic, bladder, ovarian, uterine, endometrial,
colon, gastrointestinal, head and neck and rectal cancer [5,13,35–41]. For example, PDOs
generated from colorectal cancer patients have been successfully used to evaluate their
responses to inhibitors of Tankyrase, which modulate Wnt signalling [42]. Furthermore,
novel drugs can be effectively tested in organoids, such as the tubulin-binding drug plo-
cabulin, which was shown to be potently cytotoxic to PDOs derived from colorectal cancer
patients [6].
Crucially, the response to drugs also correlated with their known genomic alterations,
such as the sensitivity of PDOs from breast and lung cancer patients with BRCA mutations
to inhibitors of poly ADP ribose polymerase (PARP), due to their impaired DNA damage
response [14,29]. These results in organoids matched with observations in PDX and clinical
drug tests. Organoids derived from ovarian cancers harbouring mutations in BRCA1 also
predicted their sensitivity to platinum drugs, paclitaxel and PARP inhibitors, in comparison
to organoids derived from clear cell ovarian cancer, which were resistant to conventional
therapies [43]. Similarly, sensitivity to the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor drug Erlotinib correlated with EGFR-mutations in lung cancer-derived
organoids [29]. Additionally, in PDOs derived from ovarian cancers, the sensitivity to
inhibitors of the kinases CHK1 and ATR, which induce replication stress, was associated
with the replication fork defects [36]. Interestingly, given the frequency of p53 mutations
in cancers, a drug which rescues p53 function (ReACp53) induced apoptosis in organoids
with mutations in p53 [44]. Furthermore, the response of organoids to radiation in these ex
vivo models also correlated with the response observed in matched patients [40,41], and
can be used to test the feasibility of new radiotherapeutic approaches [9].
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Importantly, unwanted side-effects in normal tissues can also be studied in organoid
models [45]. These adverse drug reactions are a major clinical problem, limiting the dose
and effectiveness of drugs. Organoids have been used to accurately predict potential toxici-
ties to many of the non-target tissues affected, including intestinal, renal, hepatic, cardiac
and neuronal models [46]. A method for establishing organoids from non-tumour tissue
was also recently described [47], demonstrating that it is possible to culture non-tumour
PDOs, and this will provide an important tool for evaluating the effects of therapy on
tumour and non-tumour tissues from the same patient. For example, the induction of
hyposalivation, a serious side effect of radiotherapy for head and neck cancer, can be pre-
dicted from organoids derived from patients’ salivary glands [48]. Similarly, 3D cultures of
organoids derived from liver have been used to evaluate drug-induced hepatotoxicity [28],
organoids from kidney predicted nephrotoxicity in response to cisplatin [49] and drug-
induced neurotoxicity was investigated in brain organoids [50]. Potential side effects of
therapy can also be tested using matched organoids from tumour and normal tissue. This
was demonstrated by Driehuis et al., who used PDOs from head and neck tumour tissue
and adjoining non-tumour tissue to evaluate the effects of EGFR-targeted photodynamic
therapy [51]. This study showed that EGFR expression in tumour tissue mimicked that in
patients and correlated with the response to therapy.
4. Cancer Biomarkers
Cancer biomarkers are an important tool for stratifying patients and predicting their
response to therapy. Although biomarkers have been successfully identified for some can-
cer types, such as breast cancer, which has led to the optimization of drug therapy, many
other cancer types have no or few biomarkers which predict response to therapy. Liquid
biopsies, particularly blood samples, are non-invasive and may be utilized to detect potential
biomarkers, such as circulating tumour cells, methylated DNA, cell free DNA, circulating
RNA (including microRNA) and extracellular vesicles (including exosomes) [52,53]. The
identification of potential predictive biomarkers will help to understand the sensitivity or
resistance to therapies, mechanisms of drug resistance and interactions of combination thera-
pies, and this will be augmented by the use of organoid models, as has been demonstrated in
several cancer types.
Crucially, the expression of characteristic biomarkers was more likely to be retained
in PDOs than two-dimensional culture models [54]. For example, the response of colon
cancer organoids to the inhibition of the histone methyltransferase EZH2 was correlated to
expression of the pro-apoptotic BIK gene [55]. Similarly, the resistance of cholangiocarci-
noma organoids to inhibitors of the heat shock protein HSP90 appeared to be mediated by
the expression of the microRNA miRNA21 [2]. Levels of DNA methyltransferases were
identified as a biomarker of sensitivity to decitabine using breast cancer organoids, indicat-
ing its mechanism of action and guiding drug selection in the clinic [56]. Gene expression
profiling of organoids derived from biliary tract carcinomas has also identified several
novel prognostic biomarkers, predicting outcome and drug sensitivity in these cancers [57].
Importantly, in the absence of suitable biomarkers, the effects of chemotherapy and the
development of resistance could be investigated using organoids derived from patients at
different stages of their therapy. Furthermore, the use of organoid models has been used to
predict interactions of combination therapies. Although the use of EGFR inhibitors has been
unsuccessful in unselected gastro-oesophageal adenocarcinoma patients, the EGFR copy
number can be measured using tissue and liquid biopsies, allowing the selection of patients
based on EGFR status. The interaction of drugs targeting EGFR with chemotherapy has
recently been demonstrated using PDOs from these patients, with an antagonistic effect ob-
served between anti-EGFR agents and the anthracycline chemotherapeutic epirubicin [58].
This will have important implications for the design of future combinatorial trials and
indicates that patient selection using biomarkers can be effectively modelled in patient-
derived organoids. The identification of diagnostic biomarkers may also be possible using
organoids, as demonstrated by the detection of mutations in cell-free DNA (cfDNA) from
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conditioned media from organoids derived from pancreatic ductal adenocarcinoma [59].
Importantly, these genetic alterations recapitulated the mutational profile of the primary
tumour and indicate the potential use of cfDNA as a diagnostic marker.
5. Tumour Microenvironment
Although organoids can replicate the morphology of source tissues, one common
limitation is that they are often not cultured in conditions which replicate the tumour
microenvironment (TME). The TME is comprised of the extracellular matrix (ECM) and
non-tumour cells and is highly variable depending on tumour type and location. ECM
molecules include matrix proteins, glycoproteins, glycosaminoglycans, proteoglycans,
growth factors and other secreted proteins, such as cytokines and metabolites [12]. The
composition of this matrix can influence the cell’s sensitivity or resistance to drugs or
radiation due to alterations in the levels of hypoxia, pH, the presence of inflammatory cells
or cell-adhesion-based drug resistance [60,61].
Tumour-associated stromal cells are key contributors to the TME, and there is substan-
tial crosstalk between these cells. These cells include mesenchymal cells, fibroblasts, en-
dothelial cells, adipocytes and immune cells, which secrete a variety of soluble factors, such
as pro-inflammatory cytokines, matrix metalloproteinases and growth factors [62]. It has
been shown that the presence of stromal fibroblasts in co-cultures with organoids enhanced
the maintenance of characteristics of 3D models of human tongue cancer, which were
more comparable to native tissues than co-cultures where these cells were not present [63].
Therefore, co-culture systems which accurately replicate the in vivo situation are required
in order to determine how the TME affects the response to potential therapeutic agents.
Co-cultures of PDOs with these cells will allow researchers to investigate the interaction
of tumour cells and their surrounding cells, and it has been shown that the co-culture of
PDOs with cancer-associated fibroblasts (CAFs) affects their response to chemotherapy
and immunotherapy [64,65]. Similarly, the co-culture of PDOs with lymphocytes permits
researchers to study their interactions with tumour cells. Interestingly, this approach has
also been utilized to generate patient-specific tumour-reactive T cells from peripheral blood
lymphocytes [66], allowing the interrogation of tumour sensitivity to immunotherapy.
Indeed, the use of PDOs in co-cultures is likely to facilitate in vitro screening of cellular
immunotherapies, allowing the real-time determination of patient sensitivity to these
treatments [67]. Co-cultures of PDOs derived from circulating tumour cells with CAFs
also resulted in the greater expansion of these cells in vitro [68]. Recently, a method has
been developed where organoids derived from a variety of cancers were grown at the
air–liquid interface, allowing PDOs to retain CAFs and lymphocytes with similar fea-
tures and activity to those in the tumour of origin [69]. This method closely replicates
the tumour microenvironment and preserves the immune profile required for modelling
personalized immunotherapy.
One mechanism whereby the CAFs affect resistance to therapy is the dysregulated
expression of microRNAs (miRNAs), small non-coding RNAs, which can regulate the
expression of many target genes. The upregulated expression of miRNA21 in CAFs from
pancreatic ductal adenocarcinoma (PDAC) patient tumours has been reported, and this
was associated with poor prognosis [70]. Similarly, the upregulation of miRNA21 and
miRNA221 in CAFs appeared to confer aggressiveness to pancreatic cancer cells [71], and
was associated with the hyperactive signalling of the mitogen-activated protein kinase
(MAPK) pathway in breast cancer cells and decreased response to therapy [72]. Con-
versely, the downregulation of miRNA15 and miRNA16 in CAFs promoted the growth
and progression of prostate cancer [73]. The involvement of miRNAs in CAF activity was
further demonstrated by the transformation of normal fibroblasts to CAF-like cells by
miRNAs [74,75]. Furthermore, it has been demonstrated that modulating the expression of
miRNAs can mediate sensitivity to anti-cancer therapy in organoid models [2].
An alternative ex vivo system, similar to organoid culture and incorporating the
tumour microenvironment, is the use of precision-cut liver slices (PCLS). These can be
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obtained from both animals and humans and have been used to assess drug toxicity and
metabolism. These models retain the three-dimensional architecture and mRNA expression
of whole liver and have the advantage that hepatocytes and non-parenchymal cells are
cultured simultaneously, thus providing a more accurate model of the TME than many
other cell culture models, with cell–cell and cell–extracellular matrix interactions being
preserved. When tissue slices from hepatocellular cancer are used, they can be utilized for
preclinical drug testing and offer the benefit of being able to investigate cancer–immune
cell interactions by co-culturing with matched immune cells [76]. The use of PCLS can also
be used to identify cell signalling pathways involved in metastasis and invasion in the
liver [77]. In contrast to organoids, however, these models are limited by their short-term
survival in culture of only around 7 days, with loss of cell viability observed within 1 day of
culture and necrosis occurring from day 2 after culture [78]. However, it has been suggested
that the gene expression profiles of these slices, and their response to exogenous stimuli,
could be maintained in ex vivo culture for up to 15 days [79], demonstrating that they may
have potential applications for drug screening.
6. Emerging Technologies
6.1. High-Throughput Assays
The emergence of technologies which have the potential to overcome the limitations
of organoid culture and provide organoids as 3D models in automated, large-scale cul-
tures without the cost, time and expertise associated with primary cells is summarized in
Figure 1. The use of high-throughput screening assays is essential to develop new drugs
and combinations of therapies, and, therefore, the potential application of PDOs in this area
is currently being evaluated. These may include 3D bioprinting and microfluidic systems,
co-culture and liquid handling robots [80] among other innovations. A protocol for the
drug screening of organoids derived from human oesophageal and colorectal cancers
in 384-well plates has been described [81]. Yan et al. assessed 37 anticancer drugs in 9
gastric cancer organoids and demonstrated that the screening of organoids was feasible [3].
Therefore, it appears to be feasible to employ organoids in these assays, and it is hoped that
the modification of the culture conditions will allow the automation of the process, thus
reducing the variability while further maximizing the assays performed on each sample.
An automated platform for the high-throughput screening of patient-derived 3D organoids
has recently been described; however, this system was not able to use organoids embedded
in the extracellular matrix [82]. Using an automated platform, organoids derived from
single cells from colon cancer tissue were established in a 384-well plate format which
could be used for testing drugs in a high-throughput assay [30]. This method required
the culture of the organoids in 12-well plates for expansion before dissociation and re-
plating single cells suspended in Matrigel in 384-well plates. Similarly, Pauli et al. assessed
organoid viability in a high-throughput screen, which was then validated in patient-derived
xenograft models [35]. Many preclinical experimental models rely on the measurement
of only cell viability, which is often insufficient to determine the effectiveness of potential
chemotherapeutics. Therefore, the development of high-throughput assays which measure
both cell death and cell growth rate in response to drugs is likely to improve the success
rate for oncology drugs. Importantly, it has been demonstrated that these assays can be
applied to more complex, translationally relevant models, such as organoids [83]. A further
development is the culture of organoids in “mini-rings”, where the wells are seeded in
Matrigel around the rim of the wells [84]. This method has allowed the viability, number
and size of organoids derived from ovarian cancers to be measured after treatment with
kinase inhibitors in a 96-well plate format and offers the advantage of requiring only small
cell numbers, reducing the time for expansion and maximising the assays performed on
each sample. The generation of these organoids in mini-rings facilitates media exchange
and drug treatment, thus permitting histopathological characterization, and should fa-
cilitate automated sample handling, thus increasing their usefulness in high-throughput
screening assays [85]. Crucially, the drug sensitivities observed using this method appeared
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to correlate to patient responses [84]. It is likely that similar innovations will permit the
fully automated screening of organoids using small cell numbers, in multi-well formats,
and in short (1–2 week) timescales required for the clinic.
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 7 of 15 
 
 
these assays can be applied to more complex, translationally relevant models, such as or-
ganoids [83]. A further development is the culture of organoids in “mini-rings”, where 
the wells are seeded in Matrigel around the rim of the wells [84]. This method has allowed 
the viability, number and size of organoids derived from ovarian cancers to be measured 
after treatment with kinase inhibitors in a 96-well plate format and offers the advantage 
of requiring only small cell numbers, reducing the time for expansion and maximising the 
assays performed on each sample. The generation of these organoids in mini-rings facili-
tates media exchange and drug treatment, thus permitting histopathological characteriza-
tion, and should facilitate automated sample handling, thus increasing their usefulness in 
high-throughput screening assays [85]. Crucially, the drug sensitivities observed using 
this method appeared to correlate to patient responses [84]. It is likely that similar inno-
vations will permit the fully automated screening of organoids using s all cell numbers, 
in multi-well formats, and in short (1–2 week) timescales required for the clinic. 
 
Figure 1. Use of emerging technologies to improve organoid assays. In order to overcome the limi-
tations of organoid cultures and improve their efficiency, new developments are required. These 
are described in more detail in the text and may include (a) the use of enhanced or standardized 
protocols; (b) use of cryopreserved tissue; (c) establishment of organoids from circulating tumour 
cells; (d) co-culture with components of the tumour microenvironment; (e) assays in multi-well 
formats; (f) automated processes for establishment and testing; (g) 3D bioprinting; (h) use of or-
ganoids-on-chips. Image created with Biorender.com. 
6.2. Organoids-on-a-Chip 
Microfluidic devices have been developed which closely mimic the tissue–tissue in-
terfaces, chemical gradients and vascular perfusion of the body. These devices, which al-
low the supply of oxygen and nutrients, while removing waste products, provide a more 
accurate recapitulation of organ functionality compared to conventional two- or three-
dimensional culture systems [86]. The use of a microengineering approach has led to the 
development of so-called “organ-on-a-chip” platforms, which contain hollow microchan-
nels populated by living cells from one type of tissue or combinations of two or more 
tissue types. These microfabricated cell culture devices have been created to model normal 
human organs which retain many of the key anatomical and functional features, and have 
been shown to more closely resemble the in vivo organ than the organoids from which 
they were derived [87,88]. Organs-on-a-chip provide an accurate replication of the cell–
cell interactions of the native tissue and can closely mimic the properties of the tissue of 
origin, such as cell adhesion, migration, differentiation and function [89], and it is believed 
Figure 1. Use of emerging technologies to improve organoid assays. In order to overcome the
limitations of organoid cultures and improve their efficiency, new developments are required. These
are described in more detail in th text and may include (a) the use of e hanced or st n ardized
protocols; (b) use of i ; (c) establishment of organoids from circulating tumour cells;
(d) co-culture with comp nents of the tumour microenvironme t; (e) assay in multi-well formats;
(f) automated processes for establishment and testing; (g) 3D bioprinting; (h) use of organoids-on-
chips. Image created with Biorender.com.
6.2. Organoids-on-a-Chip
Microfluidic devices have been d veloped w i h closely mimic he tissue–tissue
interfaces, chemical gradients and vascula perfusion of the body. These d vices, which
allow the supply of oxygen and nutrients, while removing waste products, provide a
more accurate recapitulation of organ functionality compared to c venti nal two- or
three-dimensional culture systems [86]. The use of a microengineering approach as
led to the development of so-called “organ-on-a-chip” platforms, which contain hollow
microchannels populated by living cells from one type of tissue or combinations of two or
more tissue types. These microfabricated cell culture devices have been created to model
normal human organs which retain many of the key anatomical and functional features,
and have been shown to more closely resemble the in vivo organ than the organoids from
which they were derived [87,88]. Organs-on-a-chip provide an accurate replication of
the cell–cell interactions of the native tissue and can closely mimic the properties of the
tissue of origin, such as cell adhesion, migration, differentiation and function [89], and it is
believed that their development has the potential to increase the success rate and speed of
drug development [90,91].
Similar technology may offer a solution to the variability observed in organoid culture,
in terms of size, structural organization, functional capacity and gene expression [88].
Therefore, it is hoped that the combination of organ-on-a-chip technology with devel-
opments in organoid culture will substantially benefit these in vitro models. A variety
of organ-specific disease states can be effectively simulated using microfluidic organoid
chips [86], as well as normal development and differentiation, such as that demonstrated
in human brain organoids [92]. Using organoids derived from tumour tissue, it is believed
that a similar approach can be used to model tumours. An organoid-on-a-chip has also
been developed which was able to deliver drugs to organoids derived from breast cancer
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tissue through a perfusable blood vessel network [93]. This system allowed the assessment
of features of tumour progression, including migration and proliferation. Another microflu-
idic platform with vascularized microtumours was used to distinguish between drugs
which were effective in disrupting vascular networks [94]. Similar platforms, which reflect
the genetic characteristics of each patient, will provide a useful tool for the rapid assess-
ment of drug sensitivity in a clinically relevant timeframe, leading to the development of
personalized medicine. The use of fully automated microfluidics systems will also provide
a platform which can be utilized in drug testing applications. This has previously been
demonstrated using brain and liver organoids [92,95], and apoptosis induction has been
measured in organoids from small-cell lung tumours in response to the chemotherapeutic
agents cisplatin and etoposide [96].
The interaction between the tumour and its microenvironment, which affects the response
to drugs, can also be modelled using a microfluidic system. These systems have been used to
provide an insight into the interaction between circulating tumour cells and the vasculature
by demonstrating the promotion of adherence of these cells to endothelium by chemokine
CXCL12 [97]. The interaction of cancer cells with components of the tissue microenvironment
was also effectively evaluated in a study by Montanez-Sauri et al., where breast carcinoma
cells were co-cultured with fibroblasts and combinations of different ECM proteins [98]. By
growing organoids in chips lined by normal non-tumour cells, these devices can be used
to model tumour progression, expansion, invasion and metastasis [86,99]. For example,
Ying et al. demonstrated that hepatocyte growth factor from cancer-associated fibroblasts
affected cell signalling in lung cells, promoting chemoresistance to paclitaxel [100]. Similarly,
using tissue from lung cancer patients cultured in 3D gels within a microfluidic device and
co-cultured with stromal cells, sensitivities to anticancer drugs were investigated [101]. This
study also allowed the optimization of doses and combinations of drugs for patients. It is,
therefore, becoming apparent that microfluidic organoid chip technologies, which create
tissue–tissue interfaces and replicate the tumour microenvironment, represent an effective
model for the evaluation of anticancer therapies and development of personalized treatments,
and have the potential to better predict the clinical effectiveness of drugs than animal models.
6.3. Bioprinting
High-throughput screening will be also enhanced by the development of techniques
which maintain the intact morphology of organoids for histological processing. One recent
study demonstrates the use of a hydrogel-based transfer device for the histological process-
ing and immunostaining of arrays of cerebral organoids, which retained the organoid’s
features, thus improving efficiency and increasing throughput [102]. Alternatively, 3D
bioprinting, the layer-by-layer deposition of bioinks, such as tissue spheroids, ECM com-
ponents and cell-laden hydrogels [103], generates 3D constructs which can be used as
a drug screening tool. Hydrogels offer several advantages for bioprinting, as they are
durable, allow adhesion of cells and can change from liquid to semi-solid [104]. Reid et al.
demonstrated the adaption of 3D bioprinting to culture organoids of mammary epithelial
structures printed into hydrogels [105]. This generated consistent and repeatable structures
using technology which could be replicated in other laboratories. Similar 3D bioprinted
cancer models have since been generated for glioblastoma, pancreatic adenocarcinoma,
cervical tumours and hepatocarcinoma [103]. Using magnetic drives to aggregate cells into
spheroids or organoids, 3D bioprinting may also allow the production of these 3D models
to be scaled up into multi-well plates for 96-, 384- and even 1536-well formats [106], thus
supporting fully automated, high-throughput screening. A further development in bio-
printing was reported by Chadwick et al., who generated a 4D printed array for organoids
derived from glioblastoma patients which could be used to assess drug sensitivity [107].
In this case, 4D refers to 3D printing with materials which can respond to stimuli, such as
heat, by altering their 3D shape. These printed arrays used expandable/collapsible smart
material to test combination therapies, including drug targeting mTOR, PI3K, PTEN and
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DNA damage response in PDOs derived from glioblastoma, and eliminated the manual
transfer of 3D arrays and increased the compatibility with high-throughput assays [107].
6.4. Circulating Tumour Cells
Another expanding area of research is the generation of PDOs from alternative sources,
such as from cells available through liquid biopsies, due to their relative ease of attain-
ment [52]. Liquid biopsies provide a source of circulating tumour cells (CTCs), which have
metastasized from the primary tumour into the patient’s blood. These biopsies are inexpen-
sive and permit repeated sampling, unlike traditional sources of biopsies, thus allowing
the possibility of modelling disease progression and pre- and post-treatment effects in
the same patient. Although CTCs are rare (approximately 1 in 1,000,000 circulating cells),
they are useful in the diagnosis and prognosis of various cancers, and several methods
have been developed to isolate these cells for the generation of organoids. These methods
rely on the biological and physical characteristics of CTCs and often include the use of
immunoaffinity-based enrichment techniques utilising the expression of common CTC
markers, or density gradient centrifugation and filtration, which rely on the density and
size of CTCs compared to other blood components [21].
The growth of organoids derived from CTCs, which retain the histological and ge-
netic characteristics of the primary tumours, has been demonstrated from liquid biopsies
obtained from patients with several cancer types [26,27,68]. These studies indicate that
the use of CTCs has high potential for drug screening and personalized medicine and will
allow multiple organoid lines to be established from the same patients over time or during
the course of therapy. For example, 3D cultures of CTCs derived from prostate and lung
cancer patients have been shown to be applicable for the screening of drug sensitivity, and
can predict treatment response in vitro [26,108]. Furthermore, it has been demonstrated
that CTCs from small cell lung carcinoma patients, grown as explants in mice, mirror the
donor patient’s sensitivity or resistance to chemotherapy [109]. By combining technologies,
Khoo et al. described a method for the expansion and culturing of clusters and spheroids of
CTCs using a microfluidic device [110]. This method created a tumour microenvironment
that comprised feeder blood cells from the same patient blood sample in a microfabricated
device, leading to a culture efficiency of greater than 50%, and providing a platform for
drug screening. Furthermore, the phenotype of the cluster correlated with patient response
to treatment and was established after just 2 weeks of cluster formation, allowing the
potential for personalized therapy and serial sampling to monitor disease [110].
6.5. Cryopreservation
Collaborations between laboratories will be improved by methods which allow the
shipment of materials between them, such as cryopreserved tissues or organoids. In or-
der to improve the recovery rate from the cryopreservation of patient-derived organoids,
several studies have aimed to develop protocols which increase this rate. Methods have
recently described the use of commercially available freezing media which may increase the
possibility of using tissue frozen before deriving organoids. This has been demonstrated
using tissue from pancreas, colon, thyroid, lung, renal and liver tumours, where tissue was
frozen in cryopreservation solution and showed that organoid establishment was possible
from the thawed tissue [32,111]. It has also been demonstrated that organoids established
from both fresh and frozen endometrial tissue had comparable organoid formation, mor-
phology, expression of markers, proliferation rates and response to treatment [112]. This
would increase the accessibility of tissue for organoid culture and has the potential to
allow many more researchers to participate in studies using these tissues. Similarly, in an
attempt to establish organoids from breast cancer tissue from patients in remote or poorly
resourced regions, Okoli et al. demonstrated that cryopreservation after the processing
of the tissue had no detrimental effect on tissue viability [113]. A further development
in this area is the use of “in-plate cryopreservation”, which can be applied to organoids.
Prinelli et al. recently described a method for the cryopreservation of human hepatic and
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colon organoids in the basement membrane matrix in 24-well plates [114]. Cell viability,
physiology and drug sensitivity in these organoids were maintained after thawing.
7. Conclusions
Although patient-derived organoids represent an imperfect model, they are an impor-
tant area of research, as they recapitulate many functional and genetic characteristics of the
tissues from which they were derived. They have the advantage of being able to be pas-
saged, frozen, resuscitated and preserved and may be used in high-throughput screening.
PDOs are useful tools for assessing mutational profiles, and we believe one of their main
applications will be the potential of the PDO as a model for testing drugs and, in particular,
personalized therapy. These organoid models offer a cheaper and more rapid alternative to
xenograft models and are more realistic in vitro models than traditional two-dimensional
cell culture models. However, there are several limitations to these models, some of which
can be overcome through the development of standardized protocols and reagents. It is
hoped that, in the future, developing technologies, such as organoids-on-chips, 3-D bio-
printing, improved handling and imaging techniques, and the establishment of PDOs from
small biological samples, such as liquid biopsies, will continue to improve the reliability
and utilization of these models.
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